Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

International journal of cancer - 15 Jan 2017

Sclafani Francesco, Kim Tae Y, Cunningham David, Kim Tae W, Tabernero Josep, Schmoll Hans J, Roh Jae K, Kim Sun Y, Park Young S, Guren Tormod K, Hawkes Eliza, Clarke Stephen J, Ferry David, Frodin Jan-Erik, Ayers Mark, Nebozhyn Michael, Peckitt Clare, Loboda Andrey, Watkins David J

Abstract excerpt

Limited data are available on the efficacy of anti-IGF-1R agents in KRAS mutant colorectal cancer (CRC). We analysed the outcome of 69 chemorefractory, KRAS exon 2 mutant CRC patients who were enrolled in a double-blind, randomised, phase II/III study of irinotecan and cetuximab plus dalotuzumab 10 mg/kg once weekly (arm A), dalotuzumab 7.5 mg/kg every second week (arm B) or placebo (arm C). Objective response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Double-Blind Method

Share to Insulin-Like Growth Factor I

Share to Insulin-Like Growth Factor II

Share to Irinotecan

Share to Receptor, IGF Type 1

Source

Identifiers

PMID: 27681944
DOI: 10.1002/ijc.30453

Genes

KRAS
EREG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.PMID 27681944Read ↗

Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.Semantic proximity Read ↗

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.Semantic proximity Read ↗

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Cetuximab in the treatment of patients with colorectal cancer.Semantic proximity Read ↗

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.Semantic proximity Read ↗

Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing.Semantic proximity Read ↗

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.Semantic proximity Read ↗

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?Semantic proximity Read ↗

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.Semantic proximity Read ↗

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.Semantic proximity Read ↗

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.